COEP

MKT CAP:$58M

Coeptis Therapeutics, Inc.

Market Cap

$58M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$16.21+$1.57 (+10.72%)

Apr 23, 2026

Company Details

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen d...

CEO

David Mehalick

IPO Date

Dec 17, 2020

Website

coeptispharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$11M

EPS (Diluted)

$3.88

Free Cash Flow

-$7M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 19, 2026

$1MEPS -$2.81

FY 2024

Mar 27, 2025

$0EPS -$5.65

Q4 2024

Mar 27, 2025

$0EPS $4.09

Q3 2024

Nov 13, 2024

$0EPS -$0.05

Q2 2024

Aug 15, 2024

$0EPS -$0.08

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 05	$0	$0	-$134.2K
Q1 20	$0	$0	$0
Q2 20	$0	$0	-$448
Q3 20	$0	$0	$0
Q1 21	$75.0K	$75.0K	-$2M
Q3 21	$0	$0	-$7M
Q4 21	$0	$0	-$284.1K
Q1 22	$0	-$250.3K	-$16M
Q2 22	$0	-$250.3K	-$10M
Q3 22	$0	-$250.3K	-$6M
Q4 22	$0	-$250.3K	-$3M
Q4 23	$0	-$250.3K	-$3M
Q1 24	$0	-$250.2K	-$3M
Q2 24	$0	-$250.2K	-$3M
Q3 24	$0	-$431.3K	-$2M
Q4 24	$0	-$260.0K	-$2M

Valuation

Quarter	P/S	P/E
Q4 05	—	—
Q1 20	—	—
Q2 20	—	—
Q3 20	—	—
Q1 21	53528.3x	—
Q3 21	54182.4x	—
Q4 21	54509.4x	—
Q1 22	54912.8x	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 05	-$32	-$32
Q2 05	-$302.0K	-$302.0K
Q3 05	$0	$0
Q4 05	-$115.0K	-$115.0K
Q1 21	-$655.3K	-$655.3K
Q3 21	-$4M	-$8M
Q4 21	-$4M	-$4M
Q1 22	-$961.7K	-$961.7K
Q2 22	-$1M	-$1M
Q3 22	-$1M	-$1M
Q4 22	-$847.4K	-$847.4K
Q4 23	-$2M	-$2M
Q1 24	-$2M	-$2M
Q2 24	-$1M	-$1M
Q3 24	-$2M	-$2M
Q4 24	-$1M	-$1M

Capital Expenditures

Quarter	CapEx
Q1 05	$0
Q2 05	$0
Q3 05	$0
Q4 05	$0
Q1 21	$0
Q3 21	$4M
Q4 21	$0
Q1 22	$0
Q2 22	$0
Q3 22	$1
Q4 22	$0
Q4 23	$2
Q1 24	$0
Q2 24	$1
Q3 24	$0
Q4 24	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 05	—	+1280.6%
Q1 20	—	-100.0%
Q2 20	—	-99.7%
Q3 20	—	-100.0%
Q1 21	—	+1222.5%
Q3 21	—	—
Q4 21	—	+63314.3%
Q1 22	—	—
Q2 22	-100.0%	+449.2%
Q3 22	—	-20.7%
Q4 22	—	+1033.2%
Q4 23	—	-78.6%
Q1 24	—	-70.0%
Q2 24	—	-48.7%
Q3 24	—	-33.5%
Q4 24	—	-35.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 05	$0	—
Q2 05	$0	—
Q3 05	$0	—
Q4 05	$0	—
Q1 21	$0	0.0%
Q3 21	$0	—
Q4 21	$0	—
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$0	—
Q4 23	$0	—
Q1 24	$96.9K	—
Q2 24	$611.6K	—
Q3 24	$96.9K	—
Q4 24	$299.6K	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 05	—	—	—	$134.2K
Q2 20	—	—	—	$448
Q1 21	—	$2M	$2.9K	—
Q3 21	—	$7M	—	—
Q4 21	—	—	—	$284.1K
Q1 22	—	—	—	$15M
Q2 22	—	—	—	$9M
Q3 22	$20.9K	—	—	$5M
Q4 22	—	—	—	$3M
Q4 23	$1M	—	—	$2M
Q1 24	$777.1K	—	—	$2M
Q2 24	$398.8K	$2M	$5.0K	—
Q3 24	$811.8K	$1M	—	—
Q4 24	$343.9K	—	—	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$2M	$0	$2M
Q2 22	$2M	$0	$2M
Q3 22	$7M	$0	$7M
Q4 22	$4M	$0	$4M
Q1 23	$2M	$0	$2M
Q2 23	$3M	$0	$3M
Q3 23	$1M	$0	$1M
Q4 23	$1M	$0	$1M
Q1 24	$1M	$0	$1M
Q2 24	$2M	$0	$2M
Q3 24	$1M	$0	$1M
Q4 24	$532.9K	$0	$532.9K
Q1 25	$4M	$0	$4M
Q2 25	$2M	$990.6K	$3M
Q3 25	$5M	$421.7K	$5M
Q4 25	$6M	$676.6K	$6M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 05	2K	0.0%	+7.0%
Q1 20	11M	+535747.4%	+544132.7%
Q2 20	11M	0.0%	+544132.7%
Q3 20	2K	-100.0%	-21.1%
Q1 21	20M	+1287118.9%	+1015856.1%
Q3 21	20M	0.0%	+89.6%
Q4 21	9M	-54.1%	-13.0%
Q1 22	20M	+118.0%	+1287118.9%
Q2 22	20M	0.0%	0.0%
Q3 22	20M	0.0%	0.0%
Q4 22	14M	-30.1%	+52.5%
Q4 23	35M	+147.1%	+72.8%
Q1 24	36M	+0.6%	+73.9%
Q2 24	38M	+5.7%	+83.8%
Q3 24	40M	+6.0%	+178.5%
Q4 24	2M	-95.2%	-94.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 05	—	—
Q1 20	—	—
Q2 20	—	—
Q3 20	—	—
Q1 21	—	—
Q3 21	—	—
Q4 21	—	—
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	$0	5
Q4 23	$0	7
Q1 24	$0	7
Q2 24	$0	7
Q3 24	$0	7
Q4 24	$0	7

Revenue / Employee